PROM1 and neoplasm: Notably, upon EIF4G2KD, ALDH1A1, a prominent marker whose up-regulation is associated with enhanced tumor aggressiveness and therapy resistance in various cancers, including EC [34–38], was increased in expression in the CD133+ cells.